Clinical Trials

PED-CITN-03: Phase 1 Trial of Hu5F9-G4 (Magrolimab) Combined With Dinutuximab in Children and Young Adults With Relapsed and Refractory Neuroblastoma or Relapsed Osteosarcoma

Link : https://www.clinicaltrials.gov/ct2/show/NCT04751383
Status : RECRUITING
Population : Relapsed Osteosarcoma (1-35yrs)
Description : Biological: Dinutuximab, Magrolimab
PI : D. Morgenstern
Centers Opened : SickKids
Phase : I
IIST/Pharma : NCI